{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:10:36Z","timestamp":1779293436673,"version":"3.51.4"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The role of adjuvant radiotherapy in pancreatic cancer following radical surgery remains a subject of of controversy. This study aimed to more accurately screen pancreatic patients who benefit from adjuvant radiotherapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Clinicopathologic characteristics of patients with resectable pancreatic cancer were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004\u20132015). Univariate and multivariate analyses were applied to identify prognostic factors affecting patient survival. All the patients were divided into two groups, one receiving radiation and the other not. Selection bias were reduced by propensity-score matching (PSM). Kaplan-Meier analysis was used to estimate overall survival (OS) and cancer-specific survival (CSS) between the two groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Within 7097 patients, 2276 received adjuvant radiotherapy (external beam radiation), and 4821 did not. Multivariate analysis revealed that race, age, median income, sex, year of diagnosis, American Joint Committee on Cancer (AJCC) T stage, N stage, scope region lymph surgery, chemotherapy, and radiotherapy were independent predictors for overall survival of all the patients (all p &lt; 0.05). After PSM, a total of 4304 patients were included. There was no OS and CSS benefit of radiotherapy compared with no-radiotherapy (all p &gt; 0.05). Among patients with N<jats:sub>1<\/jats:sub> stage, the radiotherapy group exhibited a median overall survival (mOS) of 21 months (95% CI, 19.82 to 22.18), while the non-radiotherapy group showed a slightly lower mOS of 18 months (95% CI, 16.88 to 19.12). Similarly, in terms of median cancer-specific survival (mCSS), the radiotherapy group demonstrated a mCSS of 22 months (95% CI, 20.79 to 23.21), whereas the non-radiotherapy group had a slightly shorter mCSS of 19 months (95% CI, 17.81 to 20.19). Radiotherapy reduced the all-cause mortality rate and cancer-specific mortality rate among patients with the N<jats:sub>1<\/jats:sub> stage and T<jats:sub>4<\/jats:sub> stage (all p &lt; 0.05). In contrast, the patients in the radiotherapy group with the N<jats:sub>0<\/jats:sub> stage (mOS, 28 months versus 34 months; mCSS, 30 months versus 41months), or primary focus on the body and tail of the pancreas (mOS, 23 months versus 29 months; mCSS, 25 months versus 32 months), or T<jats:sub>1<\/jats:sub> stage (mOS, 36 months versus 113 months; mCSS, 36 months versus 104 months) exhibited a higher all-cause mortality rate and cancer-specific mortality rate compared to those without radiotherapy (all p &lt; 0.05). Subgroup analysis indicated N<jats:sub>1<\/jats:sub> stage pancreatic cancer patients with T<jats:sub>2-4<\/jats:sub> stage, primary focus on the head of the pancreas, young age of onset, and combination chemotherapy were in favor of the adjuvant radiotherapy group (all p &lt; 0.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our analysis demonstrates that adjuvant radiotherapy may be beneficial for N<jats:sub>1<\/jats:sub> stage (N+) pancreatic cancer patients who have undergone up-front radical surgery with T<jats:sub>2-4<\/jats:sub> stage, primary focus on the head of the pancreas, young age of onset, and receiving combination chemotherapy. However, radiotherapy needs to be used with caution in patients with T<jats:sub>1<\/jats:sub> stage, N<jats:sub>0<\/jats:sub> stage (N-), or primary focus on the body and tail of the pancreas. These findings may contribute to the development of personalized selection criteria for adjuvant radiotherapy in post-surgical pancreatic cancer patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0317995","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:54:37Z","timestamp":1737744877000},"page":"e0317995","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["The choice of adjuvant radiotherapy in pancreatic cancer patients after up-front radical surgery"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-2963","authenticated-orcid":true,"given":"Xia","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"10242","key":"pone.0317995.ref001","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"JD Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"pone.0317995.ref002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"RL Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"10073","key":"pone.0317995.ref003","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"JP Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"pone.0317995.ref004","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B","article-title":"Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer","volume":"59","author":"Gastrointestinal Tumor Study Group","year":"1987","journal-title":"Cancer"},{"issue":"6","key":"pone.0317995.ref005","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"JH Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"issue":"2","key":"pone.0317995.ref006","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/01.sla.0000229980.81505.44","article-title":"On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer","volume":"244","author":"MC Garofalo","year":"2006","journal-title":"Ann Surg"},{"issue":"12","key":"pone.0317995.ref007","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"JP Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0317995.ref008","doi-asserted-by":"crossref","first-page":"1109068","DOI":"10.3389\/fonc.2023.1109068","article-title":"Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy","volume":"13","author":"L Wu","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0317995.ref009","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/SLA.0000000000003242","article-title":"Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis","volume":"273","author":"SK Kamarajah","year":"2021","journal-title":"Ann Surg"},{"issue":"6","key":"pone.0317995.ref010","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/SLA.0000000000003770","article-title":"Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features","volume":"274","author":"O Moaven","year":"2021","journal-title":"Ann Surg"},{"issue":"4","key":"pone.0317995.ref011","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"MA Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"pone.0317995.ref012","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bulcan.2017.11.004","article-title":"\u00c9pid\u00e9miologie du cancer du pancr\u00e9as [Epidemiology of pancreatic cancer]","volume":"105","author":"A Drouillard","year":"2018","journal-title":"Bull Cancer"},{"issue":"3","key":"pone.0317995.ref013","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.surg.2020.06.042","article-title":"Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma","volume":"169","author":"H Kolbeinsson","year":"2021","journal-title":"Surgery"},{"issue":"12","key":"pone.0317995.ref014","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1055\/s-2008-1027790","article-title":"Chirurgie des Pankreaskarzinoms [Surgery for pancreatic cancer]","volume":"46","author":"T Welsch","year":"2008","journal-title":"Z Gastroenterol"},{"issue":"8","key":"pone.0317995.ref015","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/jso.23752","article-title":"Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis","volume":"110","author":"A Sugawara","year":"2014","journal-title":"J Surg Oncol"},{"issue":"12","key":"pone.0317995.ref016","doi-asserted-by":"crossref","first-page":"e0243170","DOI":"10.1371\/journal.pone.0243170","article-title":"The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis","volume":"15","author":"ZB Lin","year":"2020","journal-title":"PLoS One"},{"issue":"11","key":"pone.0317995.ref017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00066-008-1865-8","article-title":"Radiotherapy in pancreatic cancer","volume":"184","author":"G Klautke","year":"2008","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"pone.0317995.ref018","first-page":"36","article-title":"Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer","volume":"22","author":"MZ Baig","year":"2021","journal-title":"JOP"},{"issue":"5","key":"pone.0317995.ref019","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13651820802291233","article-title":"The anatomic location of pancreatic cancer is a prognostic factor for survival","volume":"10","author":"A Artinyan","year":"2008","journal-title":"HPB (Oxford)"},{"issue":"10","key":"pone.0317995.ref020","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.3390\/curroncol29100625","article-title":"The Effects of Radiotherapy on Pancreatic Ductal Adenocarcinoma in Patients with Liver Metastases","volume":"29","author":"L Wu","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"pone.0317995.ref021","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12885-021-08288-4","article-title":"Analysis of radiotherapy impact on survival in resected stage I\/II pancreatic cancer patients: a population-based study","volume":"21","author":"D Han","year":"2021","journal-title":"BMC Cancer"},{"key":"pone.0317995.ref022","doi-asserted-by":"crossref","first-page":"651671","DOI":"10.3389\/fonc.2021.651671","article-title":"Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis","volume":"11","author":"X Shi","year":"2021","journal-title":"Front Oncol"},{"key":"pone.0317995.ref023","doi-asserted-by":"crossref","first-page":"660215","DOI":"10.3389\/fonc.2021.660215","article-title":"Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection","volume":"11","author":"J Xing","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"pone.0317995.ref024","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cncr.28543","article-title":"Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy","volume":"120","author":"EA Mellon","year":"2014","journal-title":"Cancer"},{"key":"pone.0317995.ref025","doi-asserted-by":"crossref","first-page":"10732748221109991","DOI":"10.1177\/10732748221109991","article-title":"The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases","volume":"29","author":"AM Altman","year":"2022","journal-title":"Cancer Control"},{"issue":"4","key":"pone.0317995.ref026","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/cancers11040497","article-title":"Head and Body\/Tail Pancreatic Carcinomas Are Not the Same Tumors","volume":"11","author":"DJ Birnbaum","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"12","key":"pone.0317995.ref027","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1080\/0284186X.2018.1518593","article-title":"Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis","volume":"57","author":"FN van Erning","year":"2018","journal-title":"Acta Oncol"},{"issue":"8","key":"pone.0317995.ref028","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.3390\/cancers12082036","article-title":"The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer","volume":"12","author":"M Lee","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"pone.0317995.ref029","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/biomedicines9111706","article-title":"Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location","volume":"9","author":"MK Sung","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"pone.0317995.ref030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1245\/s10434-012-2621-y","article-title":"Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm","volume":"20","author":"J Franko","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"pone.0317995.ref031","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13014-020-01561-z","article-title":"Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis","volume":"15","author":"D Wang","year":"2020","journal-title":"Radiat Oncol"},{"key":"pone.0317995.ref032","doi-asserted-by":"crossref","first-page":"799930","DOI":"10.3389\/fonc.2022.799930","article-title":"The Survival Effect of Radiotherapy on Stage IIB\/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching Analysis Based on SEER Database","volume":"12","author":"D Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"pone.0317995.ref033","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s40520-021-01821-2","article-title":"Perspectives and limits of cancer treatment in an oldest old population","volume":"33","author":"B Di Capua","year":"2021","journal-title":"Aging Clin Exp Res"},{"issue":"14","key":"pone.0317995.ref034","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"H Oettle","year":"2013","journal-title":"JAMA"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T18:54:50Z","timestamp":1737744890000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317995"}},"subtitle":[],"editor":[{"given":"Paolo","family":"Aurello","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317995","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}